CoinInsight360.com logo CoinInsight360.com logo
A company that is changing the way the world mines bitcoin

WallStreet Forex Robot 3.0
Coinpaper 2025-03-07 22:01:51

Cortical Labs Has Started Selling a 'Biocomputer' With Neural Pathways

On March 2, the firm unveiled a system called ”synthetic biological intelligence” (SBI). In it, neural networks of human cells are formed on a silicon chip, representing an ”ever-evolving organic computer.” It allows ”code to run directly on real neurons and solve today's most complex problems.” ”CL1 is the first biological computer that allows medical and research labs to test how real neurons process information, offering an ethical alternative to animal testing and providing more relevant data and insights,” the project's website says. With CL1, researchers can study brain function ”with unprecedented clarity” through biological computations that capture the adaptability and learnability of neurons in real time, revealing disease mechanisms and the impact of connections on cognition. According to the developers, SBI is capable of fast and flexible learning, making it superior to silicon AI chips used to train existing large language models. ”Unlike traditional AI, our neural systems require minimal energy and training data to master complex tasks. This is not just a new computer. This is computing technology created anew,” the project's website says; Customers can buy CL1 outright or rent time with it, accessing it remotely via the cloud. Its mass rollout is expected in the second half of 2025. ”Today is the culmination of an idea that has driven Cortical Labs for almost six years. We have made some major breakthroughs in recent years [...],” commented Dr. Hong Weng Chong, founder and CEO of the startup. All the possibilities of SBI will become clearer once the system is in the hands of users, the executive added.

Read the Disclaimer : All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms (“Site”) is for your general information only, procured from third party sources. We make no warranties of any kind in relation to our content, including but not limited to accuracy and updatedness. No part of the content that we provide constitutes financial advice, legal advice or any other form of advice meant for your specific reliance for any purpose. Any use or reliance on our content is solely at your own risk and discretion. You should conduct your own research, review, analyse and verify our content before relying on them. Trading is a highly risky activity that can lead to major losses, please therefore consult your financial advisor before making any decision. No content on our Site is meant to be a solicitation or offer.